1-16 of 16
Jonathan A. Fletcher
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma

Adrian Marino-Enriquez, Jan Philipp Novotny, Doga C. Gulhan, Isabella Klooster, Antuan V. Tran, Macy Kasbo, Meijun Z. Lundberg, Wen-Bin Ou, Derrick L. Tao, Daniel F. Pilco-Janeta, Victor Y. Mao, Frank T. Zenke, Brittaney A. Leeper, Prafulla C. Gokhale, Glenn S. Cowley, Laurence H. Baker, Karla V. Ballman, David E. Root, Joachim Albers, Peter J. Park, Suzanne George, Jonathan A. Fletcher
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5128–5139.
https://doi.org/10.1158/1078-0432.CCR-23-0998
Published: 15 December 2023
View article titled, Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Open the PDF for Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma in another window
Includes: Supplementary data
Journal Articles

Abstract A013: CDK2 and CDK4/6 inhibition in GIST: Mechanisms of response and resistance

Inga-Marie Schaefer, Matthew L. Hemming, Meijun Z. Lundberg, Matthew P. Serrata, Isabel Goldaracena, Ninning Liu, Peng Yin, Joao A. Paulo, Steven P. Gygi, Suzanne George, Jeffrey A. Morgan, Monica M. Bertagnolli, Ewa T. Sicinska, Adrian Mariño-Enríquez, Jason L. Hornick, Chandrajit P. Raut, George D. Demetri, Wen-Bin Ou, Sinem K. Saka, Jonathan A. Fletcher
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): A013.
https://doi.org/10.1158/1557-3265.SARCOMAS22-A013
Published: 15 September 2022
View article titled, Abstract A013: CDK2 and CDK4/6 inhibition in GIST: Mechanisms of response and resistance
Journal Articles

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers

Suzanne George, Margaret von Mehren, Jonathan A. Fletcher, Jichao Sun, Sen Zhang, Justin R. Pritchard, John Graeme Hodgson, David Kerstein, Victor M. Rivera, Frank G. Haluska, Michael C. Heinrich
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1268–1276.
https://doi.org/10.1158/1078-0432.CCR-21-2037
Published: 01 April 2022
View article titled, Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
Open the PDF for Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors

César Serrano, Alessandro Leal, Yanan Kuang, Jeffrey A. Morgan, Constance M. Barysauskas, Jillian Phallen, Olivia Triplett, Adrián Mariño-Enríquez, Andrew J. Wagner, George D. Demetri, Victor E. Velculescu, Cloud P. Paweletz, Jonathan A. Fletcher, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7287–7293.
https://doi.org/10.1158/1078-0432.CCR-19-2150
Published: 13 December 2019
View article titled, Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
Open the PDF for Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract B16: Dystrophin is a tumor suppressor in peripheral nerve sheath tumors

Inga-Marie Schaefer, Armelle Dufresne, Nacef Bahri, Marije A. J. de Rooij, Stacy M. Yanofsky, Yuexiang Wang, Chandrajit P. Raut, Laurence H. Baker, Adrian Marino-Enriquez, Matt van de Rijn, Jonathan A. Fletcher
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (2_Supplement): B16.
https://doi.org/10.1158/1557-3265.SARCOMAS17-B16
Published: 15 January 2018
View article titled, Abstract B16: Dystrophin is a tumor suppressor in peripheral nerve sheath tumors
Journal Articles

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, Rene Gonzalez, Jose Lutzky, Steven J. O'Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil Ramaiya, Anita Giobbie-Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (10): 2289–2296.
https://doi.org/10.1158/1078-0432.CCR-14-1630
Published: 14 May 2015
View article titled, Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Open the PDF for Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition in another window
Includes: Supplementary data
Journal Articles

Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy

Thomas Van Looy, Agnieszka Wozniak, Giuseppe Floris, Raf Sciot, Haifu Li, Jasmien Wellens, Ulla Vanleeuw, Jonathan A. Fletcher, Paul W. Manley, Maria Debiec-Rychter, Patrick Schöffski
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 6071–6082.
https://doi.org/10.1158/1078-0432.CCR-14-1823
Published: 30 November 2014
View article titled, Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy
Open the PDF for Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy in another window
Includes: Supplementary data
Journal Articles

Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

Andrew P. Garner, Joseph M. Gozgit, Rana Anjum, Sadanand Vodala, Alexa Schrock, Tianjun Zhou, Cesar Serrano, Grant Eilers, Meijun Zhu, Julia Ketzer, Scott Wardwell, Yaoyu Ning, Youngchul Song, Anna Kohlmann, Frank Wang, Tim Clackson, Michael C. Heinrich, Jonathan A. Fletcher, Sebastian Bauer, Victor M. Rivera
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (22): 5745–5755.
https://doi.org/10.1158/1078-0432.CCR-14-1397
Published: 13 November 2014
View article titled, Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
Open the PDF for Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients in another window
Includes: Supplementary data
Journal Articles

Correlation of KIT and PDGFRA mutation status with sunitinib activity in imatinib-resistant GIST

Michael C. Heinrich, Robert G. Maki, Christopher L. Corless, Cristina R. Antonescu, Jonathan A. Fletcher, Christopher D. Fletcher, Xin Huang, Charles M. Baum, George D. Demetri
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): B56.
Published: 15 August 2014
View article titled, Correlation of <em>KIT</em> and <em>PDGFRA</em> mutation status with sunitinib activity in imatinib-resistant GIST
Journal Articles

A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal

Giuseppe Floris, Agnieszka Wozniak, Raf Sciot, Haifu Li, Lori Friedman, Thomas Van Looy, Jasmien Wellens, Peter Vermaelen, Christophe M. Deroose, Jonathan A. Fletcher, Maria Debiec-Rychter, Patrick Schöffski
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (3): 620–630.
https://doi.org/10.1158/1078-0432.CCR-12-2853
Published: 31 January 2013
View article titled, A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal
Open the PDF for A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment

Evangelia Razis, Panayotis Selviaridis, Stephanos Labropoulos, Jeremy L. Norris, Mei-Jun Zhu, David D. Song, Thea Kalebic, Michael Torrens, Anna Kalogera-Fountzila, George Karkavelas, Sofia Karanastasi, Jonathan A. Fletcher, George Fountzilas
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6258–6266.
https://doi.org/10.1158/1078-0432.CCR-08-1867
Published: 30 September 2009
View article titled, Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment
Open the PDF for Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment in another window
Journal Articles

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

George D. Demetri, Michael C. Heinrich, Jonathan A. Fletcher, Christopher D.M. Fletcher, Annick D. Van den Abbeele, Christopher L. Corless, Cristina R. Antonescu, Suzanne George, Jeffrey A. Morgan, Ming Hui Chen, Carlo L. Bello, Xin Huang, Darrel P. Cohen, Charles M. Baum, Robert G. Maki
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (18): 5902–5909.
https://doi.org/10.1158/1078-0432.CCR-09-0482
Published: 14 September 2009
View article titled, Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure
Open the PDF for Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure in another window
Includes: Supplementary data
Journal Articles

Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma

Xiaofeng Jiang, Jun Zhou, Noah K. Yuen, Christopher L. Corless, Michael C. Heinrich, Jonathan A. Fletcher, George D. Demetri, Hans R. Widlund, David E. Fisher, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7726–7732.
https://doi.org/10.1158/1078-0432.CCR-08-1144
Published: 01 December 2008
View article titled, Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
Open the PDF for Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma in another window
Journal Articles

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

Michael C. Heinrich, Heikki Joensuu, George D. Demetri, Christopher L. Corless, Jane Apperley, Jonathan A. Fletcher, Denis Soulieres, Stephan Dirnhofer, Amy Harlow, Ajia Town, Arin McKinley, Shane G. Supple, John Seymour, Lilla Di Scala, Allan van Oosterom, Richard Herrmann, Zariana Nikolova, and Grant McArthur, for the Imatinib Target Exploration Consortium Study B2225
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2717–2725.
https://doi.org/10.1158/1078-0432.CCR-07-4575
Published: 01 May 2008
View article titled, Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases
Open the PDF for Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases in another window
Journal Articles

Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors

Jayesh Desai, Sridhar Shankar, Michael C. Heinrich, Jonathan A. Fletcher, Christopher D. Fletcher, Judi Manola, Jeffrey A. Morgan, Christopher L. Corless, Suzanne George, Kemal Tuncali, Stuart G. Silverman, Annick D. Van den Abbeele, Eric van Sonnenberg, George D. Demetri
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5398–5405.
https://doi.org/10.1158/1078-0432.CCR-06-0858
Published: 17 September 2007
View article titled, Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors
Open the PDF for Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors in another window
Journal Articles

Soft Tissue Sarcomas of Adults: State of the Translational Science

Ernest C. Borden, Laurence H. Baker, Robert S. Bell, Vivien Bramwell, George D. Demetri, Burton L. Eisenberg, Christopher D. M. Fletcher, Jonathan A. Fletcher, Marc Ladanyi, Paul Meltzer, Brian O’Sullivan, David R. Parkinson, Peter W. T. Pisters, Scott Saxman, Samuel Singer, Murali Sundaram, Allan T. van Oosterom, Jaap Verweij, Jill Waalen, Sharon W. Weiss, Murray F. Brennan
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (6): 1941–1956.
Published: 01 June 2003
View article titled, Soft Tissue Sarcomas of Adults: <subtitle>State of the Translational Science</subtitle>
Open the PDF for Soft Tissue Sarcomas of Adults: <subtitle>State of the Translational Science</subtitle> in another window